Fluidigm Corporation (FLDM) is Reiterated by Mizuho to Buy, Raises Price Target to $ 11

Fluidigm Corporation (FLDM) was Reiterated by Mizuho to “Buy” according to the research note released today. The brokerage firm has raised the Price Target to $ 11 from a previous price target of $8 . Mizuho advised their investors in a research report released on May 5, 2016.

Many Wall Street Analysts have commented on Fluidigm Corporation. Shares were Reiterated by Leerink Partners on Apr 12, 2016 to “Outperform” and Lowered the Price Target to $ 15 from a previous price target of $20 .

On the company’s financial health, Fluidigm Corporation reported $-0.40 EPS for the quarter, beating the analyst consensus estimate by $ 0.07 according to the earnings call on May 5, 2016. Analyst had a consensus of $-0.47. The company had revenue of $29.00 million for the quarter, compared to analysts expectations of $26.95 million. The company’s revenue was up 8.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.25 EPS.

Fluidigm Corporation closed down -0.91 points or -9.45% at $8.72 with 5,67,877 shares getting traded on Wednesday. Post opening the session at $9.57, the shares hit an intraday low of $8.65 and an intraday high of $9.71 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.

In a different news, on Nov 6, 2015, Gajus Vincent Worthington (PRESIDENT & CEO) sold 6,000 shares at $11.50 per share price. According to the SEC, on Jun 18, 2015, Vikram Jog (CHIEF FINANCIAL OFFICER) sold 3,550 shares at $25.00 per share price. On Jun 17, 2015, William Maxwell Smith (EVP, LEGAL AFFAIRS & GC) sold 3,000 shares at $24.20 per share price, according to the Form-4 filing with the securities and exchange commission.

Fluidigm Corporation creates manufactures and market technologies and life science tools focused on the exploration and analysis of single cells as well as the industrial application of genomics based upon the Company’s core microfluidics and mass cytometry technologies. The Company also offers instruments and consumables to academic institutions clinical laboratories pharmaceutical biotechnology and agricultural biotechnology (Ag-Bio) companies. The Company sells technologies and life-science tools including analytical and preparatory systems for genomic and proteomic analysis and consumables including Integrated Fluidic Circuits (IFCs) assays and reagents. The Company’s products include C1 Single-Cell Auto Prep System; Access Array System; Biomark HD System; EP1 System; CyTOF 2 System; IFCs include C1 IFCs; Access Array IFC; Dynamic Array IFCs; Digital Array IFCs; Flex Six IFC; Access Array Target-Specific Primers and Maxpar Reagents among others.

Fluidigm Corporation

Leave a Reply

Fluidigm Corporation - Is it time to Sell?

Top Brokerage Firms are advising their investors on Fluidigm Corporation. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.